Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Share your knowledge and expertise with your regulatory peers by submitting an in-depth, evidence-based article focusing on key areas and emerging issues in the global regulatory landscape.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
RAPS Euro Convergence brings regulatory peers from the EU and worldwide together in one forum to gain insights and exchange ideas on the region's most pressing issues. Register today to attend 10-12 May 2021.
Registration is now open for RAPS Convergence 2021! Gather with the regulatory community 12-15 September for four days of learning, engagement, and excitement.
With contributions from more than 30 authors from seven countries, the new edition incorporates a global overview of the field and is designed to help you get the most out of your regulatory intelligence endeavors.
Regipedia is an interactive resource created to benefit RAPS members with 24/7 access to more than 2,300 regulatory terms.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
The RAPS store will be under maintenance Saturday, 17 April between 5 AM and 12 PM EST. Store functionality may be unavailable at times during this window. We apologize for any inconvenience caused during this time.
Posted 16 April 2012 | By Alexander Gaffney, RAC
Some terminally ill patients are turning research and development into a DIY enterprise, frustrated at the pace of getting potentially life-saving treatments through the US Food and Drug Administration (FDA), reports The Wall Street Journal.
"We simply don't have time to wait for the results of [clinical trials]," said Ben Harris, who suffers from Lou Gehrig's Disease (ALS), to the Journal. "Our life spans are much shorter than the [Food and Drug Administration] approval process."
Patients suffering from ALS, like Mr. Harris, are increasingly turning to home-brewed drugs to treat their condition, says the Journal, and they're getting information on how to do it from some unlikely sources: other clinical trials participants and patent filings.
Patients have taken to tracking down research papers, obtaining chemicals, researching patent filings, and obtaining outside consultants to engineer their own medications.
"Fueled by the desperation that comes with having a fatal illness, ALS patients have used the Internet to swap information with others who are in the trial for NP001, a compound made by Neuraltus Pharmaceuticals Inc., a small biotech in Palo Alto, Calif," reports the Journal. "They also tracked down the company's public filings, such as patents, and read scientific papers published by the researchers and doctors involved with the testing. NP001 is designed to treat inflammation of the central nervous system and hopefully slow down the progression of the disease."
All of this has some experts concerned, including Jonathan Glass of the Emory University School of Medicine's ALS Center. "These people could hurt themselves," explains Glass. "Who knows what they are actually making in their kitchen."
"I feel their pain that they really want it to happen faster, but I don't think you can do it without the medical establishment," added Glass, who noted working with regulatory officials to speed up the process would have added benefits to other patients.
Read more:
Wall Street Journal - Frustrated ALS Patients Concoct Their Own Drug
Tags: R&D, DIY, ALS, Latest News, pharmaceutical, development, drug, regulatory
Regulatory Focus newsletters
All the biggest regulatory news and happenings.